XIENCE Sierra vs. Resolute Onyx

XIENCE Sierra is specifically designed for the treatment of complex patients. Its design engineering, polymer selection and proven clinical safety data make it a leading choice in complex PCI.

Greatest Longitudinal Strength of Any DES1

Best-in-Class Longitudinal Strength for Complex Lesions and Re-Cross1

Displacement of 50 gf Load (mm) Average




Resolute Onyx











The XIENCE Sierra Stent Design has 3 links per ring that connects peaks of one ring to the valleys of the adjacent ring. This design prevents rings from compressing together and stretching apart (elongating).

Design Drives Conformability

Resolute Onyx's fewer weld points may be the cause of worse longitudinal stent deformation. Resolute Onyx also demonstrates more 'clamshells' and 'trainwrecks' when evaluating conformability2.


Treating Side Branches and Large Vessels with XIENCE Sierra Vs. Resolute Onyx

Mid-Marker Placement,1 for Precise Deliverability (both stents 3.0 x 18 mm)
Distal Stent to Mid-Marker1 (average mm) 0 1.2
Proximal Stent to Mid-Marker1 (average mm) 0 1.1
Side Branch Accessibility1,9
Maximum Circular Side Branch Area Diameter
2.04 mm

Maximum Circular Side Branch Area Diameter
1.64 mm

XIENCE Fluoropolymer Vs. Resolute Onyx Polymer

XIENCE has been shown to have superior thromboresistant properties compared to the BioLinx polymer in pre-clinical experiments3.

XIENCE compared with other competitors

Test methodology:

  • Human blood was used to collect blood platelets, which were labeled with fluorescent dye to be visualized under confocal microscopy.
  • Devices to be tested were placed in a flow chamber and labeled platelets were circulated at physiological shear rate.

XIENCE Fluoropolymer4


XIENCE Alpine und Resolute Onyx stents tested.

XIENCE demonstrates nearly half the stent thrombosis rate of Resolute Onyx and Resolute Integrity at 1 year in multiple trials.

AR Definite/Probable Stent Thrombosis

Core Trial6
RESOLUTE Integrity
All-Comers Trial5

NOTE: Results from clinical trials are not directly comparable. Information provided for educational purposes only.

XIENCE shows a lower TLF rate at 2 years than Resolute Onyx at 1 year

Target Lesion Failure at 1 or 2 Years

NOTE: Results from clinical trials are not directly comparable. Information provided for educational purposes only.

TLF in Resolute Onyx Core Trial defined as cardiac death, target vessel-myocardial infarction and target lesion revascularization. All other trials TLF defined as cardiac death, target vessel-myocardial infarction and ischemia driven-target lesion revascularization.

AP2947115-WBU Rev A

* Comparative claim refers to major drug-eluting stent manufacturers in U.S. market, as well as BIOTRONIK. Orsiro is not available nor for sale in the U.S. as of November 2018. 

  1. Tests performed by and data on file at Abbott. Strength measured from displacement of 50 gf load. 
  2. Data on file at Abbott. Photos taken by and on file at Abbott. All stents 3.0mm x 18mm size, expanded to nominal on a 10 mm bend.
  3. Pre-clinical experiment of real time platelet-device interaction between different stent types. Conducted by CVPath Institute.
  4. Torii, S., Kolodgie, F., Cheng, Q., Acampado, E., Mori, H., Perkins, L., Hossainy, S., Pacetti, S., Finn, A.V. and Virmani, R. (2017). Acute Thrombogenicity and Inflammation in Response to a Durable Fluoropolymer Everolimus-Eluting Stent Relative to a Durable BioLinx polymer Zotarolimus-Eluting Stent. Journal of the American College of Cardiology 70, B201. Notes: Pre-clinical study using an ex vivo porcine shunt model with platelet aggregation evaluated by confocal microscopy with immunofluorescent staining against dual platelet markers (CD61/CD42b) along with scanning electron microscopy.
  5. Serruys P et al. “Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents” NEJM 2010. 
  6. Price M, et al. “Twelve Month Follow Up Data From the Onyx Core Trial: Angiographic and Clinical Performance of Next Generation Resolute Onyx Drug-Eluting Stent” Poster, ACC 2017 
  7. Kereiakes, D. et al. “Late Clinical Outcomes after Bioresorbable or Permanent Polymer Everolimus-Stents: 2 Year Results from the EVOLVE II Randomized Trial.” ACC 2016
  8. Stone G, et al. "Three Year Clinical Outcomes from the SPIRIT IV Trial" TCT 2011. 
  9. Tests performed. A 3.0 mm stent's side branch was opened up with a 3.0 mm dilation balloon. Measure the maximum circular side branch area diameter.

You are about to leave the Abbott family of websites for a third party website.

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott.

The website that you have requested also may not be optimized for your screen size.

Do you wish to continue and exit the website?
Important safety information